Dr. Marcel van Duin is the Chief Scientific Officer and Head of External Innovation and Emerging Science at Organon, a company with the vision to advance the health of women.
Marcel was previously Vice President, Head of R&D Alliances for Reproductive Medicine and Maternal Health (RM&MH) and Therapeutic Area Head for Research in RM&MH at Ferring Pharmaceuticals and member of the global drug discovery leadership team. Key scientific focus was on projects for endometriosis, infertility, and obstetrical complications such as preterm labor and preeclampsia as well as a strong outreach to external opportunities.

Before that, his career spanned leadership R&D responsibilities in multiple women’s health areas in Merck & Co, Schering Plough and Organon where he started his professional journey in the pharmaceutical industry in Oss, the Netherlands.
Marcel holds a B.S. in biology from Utrecht university and PhD at Erasmus university, Rotterdam, both in the Netherlands.

At present he holds an honorary professorship in Innovation at the Chinese Academy of Sciences in Beijing, China. He has (co-)authored over 60 scientific publications.

Organon is a global healthcare company formed through a spinoff from Merck & Co., Inc. (known as MSD outside of the U.S. and Canada) with a mission to deliver impactful medicines and solutions for a healthier every day. We build upon our strong foundation of more than 60 medicines and other products across a range of areas including reproductive health, heart disease, dermatology, allergies and asthma.

We bring these important therapies around the world, with an international footprint that serves people in more than 140 markets. We believe the diversity of our business provides a sustainable engine of growth so we can continue to invest in and advance new medicines and treatments for women that are so urgently needed.

We are here for her health.